TLTFF - Theralase Technologies Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1793
-0.0019 (-1.05%)
At close: 2:30PM EDT
Stock chart is not supported by your current browser
Previous Close0.1812
Open0.1890
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1752 - 0.1890
52 Week Range0.1600 - 0.4500
Volume63,505
Avg. Volume293,425
Market Cap36.256M
Beta (3Y Monthly)1.23
PE Ratio (TTM)N/A
EPS (TTM)-0.0220
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE

    Theralase Grants Stock Options

    TORONTO, ON / ACCESSWIRE / September 16, 2019 / Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage biopharmaceutical company developing Anti-Cancer treatments with their light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, today announces the grant of stock options. The Company has granted an aggregate of 12,340,000 stock options to directors, officers, employees & advisory board members pursuant to the Company’s stock option plan.

  • ACCESSWIRE

    Theralase Annouces First Patient Treated in Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

    TORONTO, ON / ACCESSWIRE / September 4, 2019 / Theralase ® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage biopharmaceutical company developing Anti-Cancer ...

  • ACCESSWIRE

    Theralase Releases Second Quarter 2019 Financial Results and Company Update

    TORONTO, ON / ACCESSWIRE / August 29, 2019 / Theralase® Technologies Inc. (" Theralase " or " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated ...

  • ACCESSWIRE

    Theralase Announces Pricing Of Prospectus Offering

    TORONTO, ON / ACCESSWIRE / August 1, 2019 / Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, is pleased to announce today the price of its marketed public offering previously announced on June 26, 2019 (the “Offering”). The Offering will be conducted at a price of $0.30 per unit of the Company (a “Unit”) for minimum gross proceeds of $7,500,000 and maximum gross proceeds of $15,000,000 (the “Offering”). Each Unit will be comprised of one common share of the Company (the “Common Shares”) and one common share purchase warrant (the “Warrants”).

  • ACCESSWIRE

    Patient Five Cancer-Free Eighteen Months After Single Anti-Cancer Treatment

    TORONTO, ON / ACCESSWIRE / July 31, 2019 / Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers reports that patient five, enrolled and treated in the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”), has demonstrated no tumour recurrence, progression or presence of NMIBC disease at the 540 day clinical and cystoscopy assessment. The Study’s purpose was to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy, primarily at 90 days and secondarily at 180 days post treatment.

  • ACCESSWIRE

    McGill University Health Centre Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

    MUHC is one of the leading academic health centres in the world and attracts clinical and research expertise from around the world, assessing the latest in medical technology and training the next generation of medical professionals.

  • ACCESSWIRE

    Theralase Enrolls First Patient into Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

    TORONTO, ON / ACCESSWIRE / July 29, 2019 / Theralase® Technologies Inc. (“Theralase” or the “Company”) (TLT: TSXV) (TLTFF: OTCQB), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations, intended to safely and effectively destroy various cancers, announced today that the first patient has been enrolled into its Phase II clinical study titled “Patients with Non-Muscle Invasive Bladder Cancer (“NMIBC”), who present with Carcinoma In-Situ (“CIS”), who are considered Bacillus Calmette Guérin (“BCG”) Unresponsive or are intolerant to BCG Therapy (“Phase II”)” at University Health Network (“UHN”) in Toronto. Phase II has been designed in compliance with FDA industry guidelines for BCG-unresponsive NMIBC (issued:February 2018) and defined by the FDA in a Pre-Investigational New Drug (“IND”) conference call in late June 2019.

  • ACCESSWIRE

    Theralase Signs Agreement with Urology Organization to Provide US Clinical Study Sites for its Phase II Non Muscle Invasive Bladder Cancer Clinical Study

    TORONTO, ON / ACCESSWIRE / July 24, 2019 / Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, is pleased to announce that the Company has signed an agreement with a Trial Management Organization (“TMO”) to provide 4 to 6 US based urology study sites that will be able to commence enrolling and treating patients, subject to Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) approval for its Phase II Non Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study (“Study II”). The TMO is in discussions with approximately 14 potential US based clinical study sites that are large integrated clinical urology practices.

  • ACCESSWIRE

    Theralase Receives Notice of Acceptance for Multiwavelength Photo Dynamic Therapy from Russian Patent Office

    TORONTO, ON / ACCESSWIRE / July 16, 2019 / Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations to safely and effectively destroy various cancers is pleased to announce that the Russian Patent Office has issued a Notice of Acceptance for a Multiwavelength Photo Dynamic Therapy (“PDT”) patent application. The patent application entitled, “Apparatus and Method for Multiwavelength Photo Dynamic Therapy” will issue into a patent later this year and provides additional international patent protection for the Company in the application of Theralase’s PDT technology for cancer.

  • ACCESSWIRE

    Theralase Releases 2019 Annual General Meeting Video Presentations

    TORONTO, ON / ACCESSWIRE / June 28, 2019 / Theralase ® Technologies Inc. (" Theralase " or the " Company ") ( TLT:TSXV ) ( TLTFF:OTCQB ), a clinical stage pharmaceutical company dedicated ...

  • ACCESSWIRE

    Regulatory Updates from Health Canada and US FDA

    TORONTO, ON / ACCESSWIRE / June 27, 2019 / Theralase ® Technologies Inc. (" Theralase " or " Company ") ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company dedicated ...

  • ACCESSWIRE

    Health Canada Approves Amended Clinical Trial Application

    TORONTO, ON / ACCESSWIRE / June 26, 2019 / Theralase ® Technologies Inc. (" Theralase " or " Company ") ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company dedicated ...

  • ACCESSWIRE

    Theralase Brain Cancer Pre-Clinical Research Accepted for Publication

    TORONTO, ON / ACCESSWIRE / June 25, 2019 / Theralase® Technologies Inc. ("Theralase" or "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that a scientific paper pertaining to the Company's Rutherrin® based PhotoDynamic Therapy ("PDT") has been peer reviewed and selected for publication in Neuro-Oncology Advances ("NOA"). Publication in NOA of Theralase's latest pre-clinical research of Rutherrin® PDT treatment targeting GlioBlastoma Multiforme ("GBM"), assisted through a collaboration with researchers at University Health Network's ("UHN") Princess Margaret Cancer Centre, allows many specialists in the field of neuro-oncology the opportunity to learn about Theralase's advances in this field.

  • ACCESSWIRE

    Theralase Releases Amended and Restated 1Q2019 Financial Statements

    TORONTO, ON / ACCESSWIRE / June 18, 2019 / Theralase® Technologies Inc. ("Theralase" or "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers filed its amended and restated condensed interim consolidated financial statements and Management Discussion and Analysis ("MD&A") as at and for the three-months ended March 31, 2019. Management of the Company has determined that the property lease for the Company's premises and office equipment was not properly recorded under International Financial Reporting Standards ("IFRS") 16 Leases, which came into effect on January 1, 2019 and provides guidance on how to recognize, measure, present and disclose leases.

  • ACCESSWIRE

    Theralase Releases 1Q 2019 Financial Statements

    TORONTO, ON / ACCESSWIRE / May 30, 2019 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers released its 1Q2019 financial statements. Total revenue for the three-month period ended March 31, 2019, decreased to $121,179 from $441,193 for the same period in 2018, a 73% decrease. In the US, revenue decreased 94% to $5,075 from $90,354 and international revenue decreased 100% from $53,778 to $Nil during the three-month period ended March 31, 2019.

  • ACCESSWIRE

    Theralase Granted Notice of Acceptance for PhotoDynamic Compounds by Chinese Patent Office

    TORONTO, ON / ACESSWIRE / May 20, 2019 / Theralase ® Technologies Inc. (" Theralase " or the " Company ") ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company dedicated ...

  • ACCESSWIRE

    Theralase’s 5th Annual Medical and Scientific Advisory Board Meeting Advances Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

    TORONTO, ON / ACCESSWIRE / May 13, 2019 / Theralase® Technologies Inc. (" Theralase " or the " Company ") ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company dedicated ...

  • ACCESSWIRE

    Chinese Patent Office Issues Notice of Acceptance for Multiwavelength PhotoDynamic Therapy

    TORONTO, ON / ACCESSWIRE / May 7, 2019 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that the Chinese Patent Office has Issued a Notice of Acceptance for a patent application concerning Multiwavelength PhotoDynamic Therapy ("PDT") to the Company. The patent entitled, "Apparatus and Method for Multiwavelength PhotoDynamic Therapy" validates the proprietary position of the Company and opens opportunities for the application of Theralase's PDT technology in an international market.

  • ACCESSWIRE

    Theralase's Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study Research Presented at the American Urological Association

    TORONTO, ON / ACCESSWIRE / May 6, 2019 / Theralase ® Technologies Inc. ('' Theralase '' or the '' Company '') ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company dedicated to the research ...

  • ACCESSWIRE

    Theralase Commences Phase II NMIBC Clinical Study

    TORONTO, ON / ACCESSWIRE / April 25, 2019 / Theralase ® Technologies Inc. (" Theralase " or the " Company ") ( TLT:TSXV ) ( TLTFF:OTCQB ), a clinical stage pharmaceutical company dedicated ...

  • ACCESSWIRE

    Theralase's Latest Scientific Research to be Presented at the 17th Annual International Photodynamic Association World Congress

    Nine Scientific Papers Detailing the Latest Scientific Research of Theralase ® 's Anti-Cancer Technology ("ACT") Platform have been Peer Reviewed and will be Presented at the International Photodynamic ...

  • ACCESSWIRE

    Theralase(R) Releases 2018 Year End Audited Financial Statements

    TORONTO, ON / ACCESSWIRE / April 17, 2019 /Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers released the audited financial statements for the year ended December 31, 2018. In the US, revenue increased 16% to $304,785 from $261,833 and international revenue increased 62% to $223,975 from $138,665. The decrease in total revenue in 2018 is primarily due to the restructuring of the sales and marketing departments resulting in the termination of certain sales and marketing personnel and decreased spending in advertising.

  • ACCESSWIRE

    Patient Six Cancer-Free Twelve Months After Single Anti-Cancer Treatment

    Results of Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study Demonstrate a 66% Complete Response ("CR") at the Therapeutic Dose (0.70 mg/cm2) 360 Days Post Treatment ...

  • ACCESSWIRE

    Theralase’s Phase IB Clinical Study to be Presented at the 17(th) International Photodynamic Association World Congress

    TORONTO, ON / ACCESSWIRE / MARCH 26, 2019 /Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that the results of the Phase Ib clinical study will be presented at the 17th International Photodynamic Association ("IPA") World Congress, to be held in Cambridge, Massachusetts from June 28th to July 4th, 2019. IPA has been bringing together researchers and clinicians in all fields of PhotoDynamic Therapy ("PDT") and PhotoDiagnosis ("PD") since 1986.

  • ACCESSWIRE

    Theralase Granted United States Patent to Destroy Cancer Cells with X-Ray Activated Photo Dynamic Compounds

    TORONTO, ONTRAIO / ACCESSWIRE / March 4, 2019 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations intended to safely and effectively destroy various cancers, announced today that it has been granted allowance for a United States patent to issue later this year for destroying cancer cells with X-ray activated PDCs. Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer of Theralase® and the lead inventor of the technology stated that, "In 2019, the Company plans to commence a Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study, which if successful may lead to commercialization of this technology in Canada, the United States and the European Union.